Peter Hedera, MD
Neurology · Louisville, KYNPI 1518041615
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.3%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 35.7% of the total. Among neurology clinicians in KY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 213 payments — averaging $870.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$66K
- Ipsen Biopharmaceuticals, Inc$42K
- AstraZeneca$33K
- AbbVie$23K
- MDD US Operations, LLC$9K
- Orphalan Inc$4K
- plus $9K from 13 others
Across 224 payments — averaging $1129.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ipsen Pharma SAS$91K
- Neurocrine Biosciences, Inc.$57K
- MDD US Operations, LLC$52K
- UCB SA$27K
- Jazz Pharmaceuticals Inc.$26K
- Avanir Pharmaceuticals, Inc.$490
What the payments were for
- Consulting fees$84,06445%
- Speaking & faculty fees$80,44843%
- Travel & lodging$13,2277%
- Food & beverage$7,6834%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 65 | $66,182 |
| Ipsen Biopharmaceuticals, Inc | 27 | $42,106 |
| AstraZeneca | 10 | $33,045 |
| AbbVie | 21 | $22,604 |
| MDD US Operations, LLC | 32 | $8,722 |
| Orphalan Inc | 3 | $4,235 |
| Bayer | 12 | $1,848 |
| Abbott | 8 | $1,711 |
| Vertex | 3 | $1,475 |
| Boston Scientific | 10 | $1,426 |
| Ipsen Pharma SAS | 3 | $743 |
| Amneal Pharmaceuticals LLC | 3 | $414 |
| Merz Pharmaceuticals, LLC | 3 | $310 |
| Medtronic(2 entities) | 4 | $209 |
| Eli Lilly | 1 | $150 |
| Teva Pharmaceuticals USA, Inc. | 2 | $138 |
| Amgen | 3 | $68 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Supernus Pharmaceuticals, Inc. | 2 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$185,421 in reported general payments places this provider in the 95th percentile of 210 neurology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 101 | $543,172 |
| AustedoDeutetrabenazine | 22 | $247,926 |
| IngrezzaValbenazine Tosylate | 12 | $97,070 |
| GocovriAmantadine Hcl | 28 | $83,379 |
| Austedo XrDeutetrabenazine | 13 | $63,699 |
| RytaryCarbidopa/Levodopa | 35 | $41,460 |
| InbrijaLevodopa | 12 | $40,928 |
| NourianzIstradefylline | 18 | $38,544 |
| NeuproRotigotine | 16 | $21,048 |
| Carbidopa | 15 | $17,290 |
| Emgality PenGalcanezumab-Gnlm | 11 | $11,127 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 170 | $9,683 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 272 | $9,195 |
| Entacapone | 21 | $6,112 |
| Rasagiline Mesylate | 24 | $4,986 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $138 | $311,62635 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $66,182 | $97,07012 claims |
| MDD US Operations, LLCGocovri | $8,722 | $83,37928 claims |
| Amneal Pharmaceuticals LLCRytary | $414 | $41,46035 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 210 neurology providers in Kentucky.
Other neurology in Louisville
- Brian PlatoLouisville$232K
- Kristi NordLouisville$217K
- Angela HardwickLouisville$187K
- Jeffrey FrankLouisville$181K
- Mohammad AlsorogiLouisville$111K
- Tad SeifertLouisville$99K
- Michael SweeneyLouisville$71K
- Michael SowellLouisville$60K
- David RobertsonLouisville$58K
- Jenny FengLouisville$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.